Disease · MONDO_0001673

diarrheal disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. diarrheal disease. Diseases, record MONDO_0001673. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001673

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: diarrheal disease; Open Targets
Open Targets ID: MONDO_0001673; Open Targets
Other names: Watery stool, diarrhea, diarrheal disorder, diarrhoea, frequent stools, loose stools; Open Targets
Disease Ontology: DOID:13250; Disease Ontology
MeSH: D003967; MeSH
NCI Thesaurus: C2987; NCI Thesaurus
Highest stage of its drugs: Approval, for 21 of its 76 drugs, from DailyMed, FDA, PMDA and TTD; Open Targets

Drugs76

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NITAZOXANIDE	CHEMBL1401	Small molecule	Approval	DailyMed, FDA and TTD	10	5	5	Drugs and targets
LOPERAMIDE	CHEMBL841	Small molecule	Approval	TTD	7	5	5	Drugs and targets
RACECADOTRIL	CHEMBL2103772	Small molecule	Approval	TTD	6	5	5	Drugs and targets
RIFAXIMIN	CHEMBL1617	Small molecule	Approval	DailyMed	8	4	4	Drugs and targets
CROFELEMER	CHEMBL2108184	Small molecule	Approval	DailyMed and FDA	6	4	4	Drugs and targets
VANCOMYCIN	CHEMBL262777	Small molecule	Approval	FDA	5	4	4	Drugs and targets
RIFAMYCIN SODIUM	CHEMBL2105680	Small molecule	Approval	DailyMed and FDA	4	2	1	Drugs and targets
ELUXADOLINE	CHEMBL2159122	Small molecule	Approval	EMA Human Drugs, at withdrawal	3	2	2	Drugs and targets
LOPERAMIDE HYDROCHLORIDE	CHEMBL1707	Small molecule	Approval	DailyMed	39	1	1	Drugs and targets
BISMUTH SUBSALICYLATE	CHEMBL1120	Small molecule	Approval	DailyMed	7	1	1	Drugs and targets

1 to 10 of 76

See all 76 drugs

Targets40

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	4	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
OPRM1	Mu-type opioid receptor	4	Mu opioid receptor agonist	Approval	https://conductscience.org/library/genes/4988	Drugs and targets
SSTR2	Somatostatin receptor	3	Somatostatin receptor 2 agonist; Somatostatin receptor agonist	Phase 3	https://conductscience.org/library/genes/6752	Drugs and targets
SSTR5	Somatostatin receptor	3	Somatostatin receptor 5 agonist; Somatostatin receptor agonist	Phase 3	https://conductscience.org/library/genes/6755	Drugs and targets
CFTR	Cystic fibrosis transmembrane conductance regulator	2	Cystic fibrosis transmembrane conductance regulator inhibitor	Approval	https://conductscience.org/library/genes/1080	Drugs and targets
PTGS1	Cyclooxygenase	2	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	2	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
SSTR1	Somatostatin receptor	2	Somatostatin receptor agonist	Phase 3	https://conductscience.org/library/genes/6751	Drugs and targets
SSTR3	Somatostatin receptor	2	Somatostatin receptor agonist	Phase 3	https://conductscience.org/library/genes/6753	Drugs and targets
SSTR4	Somatostatin receptor	2	Somatostatin receptor agonist	Phase 3	https://conductscience.org/library/genes/6754	Drugs and targets

1 to 10 of 40

See all 40 targets

Trials72

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00547898	Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea	Phase 3	374	2020-09-03	HIV Associated Diarrhea	CROFELEMER	Its record names the disease	ClinicalTrials.gov
NCT01142089	Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)	Phase 3	264	2018-04-10	Traveler's Diarrhea	RIFAMYCIN SODIUM	Open Targets' reading of its record	ClinicalTrials.gov
NCT01374490	Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea	Phase 3	250	2020-08-17	HIV Enteropathy, Diarrhea With HIV	CROFELEMER	Its record names the disease	ClinicalTrials.gov
NCT01718873	Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer	Phase 3	230	2023-04-12	Colorectal Cancer	BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT03633344	Efficacy of the Administration of Colloidal Silicon Dioxide in Tablet Dosage Form in Patients With Acute Diarrhea	Phase 2	145	2019-06-06	Diarrhoea;Acute	SILICON DIOXIDE	Its record names the disease	ClinicalTrials.gov
NCT00774930	An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome	Phase 3	115	2016-02-09	Carcinoid Syndrome	LANREOTIDE	Its record names the disease	ClinicalTrials.gov
NCT04150250	Cholera Anti-Secretory Treatment Trial	Phase 2	47	2021-03-25	Cholera	IOWH-032	Its record names the disease	ClinicalTrials.gov
NCT01591863	Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)	Phase 2	38	2015-03-17	Clostridium Difficile-associated Diarrhea	FIDAXOMICIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03473561	Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea	Phase 3	31	2023-11-24	Diarrhea, Infantile	RACECADOTRIL	Its record names the disease	ClinicalTrials.gov
NCT02920242	A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.	Phase 3	28	2019-03-25	Travelers' Diarrhea	RIFAXIMIN	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 72

See all 72 trials

Comparisons in its trials26

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Crofelemer 125Mg BID vs Placebo BID: Primary Efficacy Outcome is Count of Participants With Two or Less Watery Bowel Movements Per Week During at Least Two Weeks of the Treatment Phase of the Optimal Dose of Crofelemer Compared to Placebo	24 of 136	11 of 138	274	NCT00547898	Trial comparisons
Rifamycin SV MMX vs Placebo: Clinical Cure	162 of 199	35 of 65	264	NCT01142089	Trial comparisons
Rifamycin SV MMX vs Placebo: deaths from any cause	0 of 199	0 of 65	264	NCT01142089	Trial comparisons
Rifamycin SV MMX vs Placebo: serious adverse events	2 of 199	1 of 65	264	NCT01142089	Trial comparisons
Bevacizumab Before Chemotherapy vs Bevacizumab With Chemotherapy: Objective Response Rate	65 of 115	66 of 115	230	NCT01718873	Trial comparisons
Bevacizumab Before Chemotherapy vs Bevacizumab With Chemotherapy: deaths from any cause	2 of 115	2 of 115	230	NCT01718873	Trial comparisons
Bevacizumab Before Chemotherapy vs Bevacizumab With Chemotherapy: Disease Control Rate	107 of 115	103 of 115	230	NCT01718873	Trial comparisons
Bevacizumab Before Chemotherapy vs Bevacizumab With Chemotherapy: serious adverse events	65 of 115	75 of 115	230	NCT01718873	Trial comparisons
Bevacizumab Before Chemotherapy vs Bevacizumab With Chemotherapy: Toxic Effects	108 of 114	113 of 115	229	NCT01718873	Trial comparisons
Carbowhite vs Carbowhite Placebo: Compliance Rate	0 of 120	0 of 24	144	NCT03633344	Trial comparisons

1 to 10 of 26

See all 26 comparisons in its trials

Papers from its trials29

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
28575523	RESULT	1	PubMed
27214300	RESULT	1	PubMed
23323867	RESULT	1	PubMed
21871249	RESULT	1	PubMed
16601430	RESULT	1	PubMed
11171619	RESULT	1	PubMed
10440607	RESULT	1	PubMed
9712236	RESULT	1	PubMed
38604769	DERIVED	1	PubMed
37405406	DERIVED	1	PubMed

1 to 10 of 29

See all 29 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001673

GET https://conductscience.org/api/diseases/v1/MONDO_0001673/drugs?page=2

API reference For AI assistants